علاج سرطان الغدد الليمفاوية من خلايا الوشاح في المرحلة المحدودة (المرحلة الأولى–الثانية)

References

Limited stage (stage I–II) MCL is rare, forming 5%–15% of all newly diagnosed cases.

In low‐risk disease (stage I, without risk factors), observation or ISRT can be offered [II, B].

Involved site radiotherapy (24–36 Gy) is associated with high response rates and remissions may be durable, albeit mostly in stage I disease and low‐risk MIPI groups.

In patients with intermediate risk/tumor load, a shortened systemic therapy, followed by radiation, may be considered [IV, B].

In stage II with high‐risk features, systemic treatment as per advanced stage is recommended [IV, B].